Zai Lab Shares Are Trading Higher After the Company Reported Better-than-expected Q2 Sales Results. Also, the Company Said It Expects Substantial Topline Growth and Path to Achieve Profitability by the End of 2025.
Zai Lab Shares Are Trading Higher After the Company Reported Better-than-expected Q2 Sales Results. Also, the Company Said It Expects Substantial Topline Growth and Path to Achieve Profitability by the End of 2025.
再鼎医药股价上涨，公司发布Q2销售业绩优于预期。此外，公司表示预计具备实质性收入增长和在2025年底之前实现盈利路径。
Zai Lab Shares Are Trading Higher After the Company Reported Better-than-expected Q2 Sales Results. Also, the Company Said It Expects Substantial Topline Growth and Path to Achieve Profitability by the End of 2025.
再鼎医药股价上涨，公司发布Q2销售业绩优于预期。此外，公司表示预计具备实质性收入增长和在2025年底之前实现盈利路径。